Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, tacrolimus, and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
If you want to change selection, open document below and click on "Move attachment"
- (no access) - MKSAP_17.pdf, p3418
|status||not read|| ||reprioritisations|
|last reprioritisation on|| ||suggested re-reading day|
|started reading on|| ||finished reading on|